Moderna Starts Study of Hybrid Vaccine That Targets Omicron (1)

March 10, 2022, 3:41 PM UTC

Moderna Inc. said it had started a study of a booster shot that combines a formulation designed to fend off the omicron variant with the company’s current Covid-19 vaccine.

The company said in a statement Thursday that the first participant in the study had been given the experimental shot. Moderna plans to enroll about 375 people in the trial, which it said will be conducted at about 20 sites in the U.S.

The shot will be studied in adults 18 and older who previously received the two-dose primary series of Moderna’s vaccine, as well as a Moderna booster shot at ...

Learn more about Bloomberg Law or Log In to keep reading:

See Breaking News in Context

Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.

Already a subscriber?

Log in to keep reading or access research tools and resources.